{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:57Z","timestamp":1792269537669,"version":"4.4.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114957","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:18:37Z","timestamp":1787375917000},"source":"Crossref","is-referenced-by-count":1,"title":["Type II Minocycline-Induced Hyperpigmentation During Long-Term Management of an Epidermal Growth Factor Receptor (EGFR) Inhibitor-Associated Acneiform Eruption"],"prefix":"10.7759","author":[{"given":"Dakarai","family":"Dunbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma","volume":"392","author":"Srinivasan R","year":"2025","unstructured":"Srinivasan R, Gurram S, Singer EA, et al.. Bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma. N Engl J Med. 2025, 392:2346-56. 10.1056\/NEJMoa2200900","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.02.025","article-title":"Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer","volume":"69","author":"Kiyohara Y","year":"2013","unstructured":"Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013, 69:463-72. 10.1016\/j.jaad.2013.02.025","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200012","article-title":"Minocycline-induced cutaneous hyperpigmentation","volume":"192","author":"Shute L","year":"2020","unstructured":"Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. CMAJ. 2020, 192:E981. 10.1503\/cmaj.200012","journal-title":"CMAJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.08.19","article-title":"Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial)","volume":"4","author":"Arrieta O","year":"2016","unstructured":"Arrieta O, Carmona A, de Jesus Vega MT, Lopez-Mejia M, Cardona AF. Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial). Ann Transl Med. 2016, 4:313. 10.21037\/atm.2016.08.19","journal-title":"Ann Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20391","article-title":"Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/USA Delphi consensus process","volume":"39","author":"Apalla Z","year":"2025","unstructured":"Apalla Z, Freites-Martinez A, Grafanaki K, et al.. Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/USA Delphi consensus process. J Eur Acad Dermatol Venereol. 2025, 39:730-41. 10.1111\/jdv.20391","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1795","article-title":"Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center","volume":"156","author":"Yu Z","year":"2020","unstructured":"Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center. JAMA Dermatol. 2020, 156:1079-85. 10.1001\/jamadermatol.2020.1795","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464519-type-ii-minocycline-induced-hyperpigmentation-during-long-term-management-of-an-epidermal-growth-factor-receptor-egfr-inhibitor-associated-acneiform-eruption","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:18:38Z","timestamp":1787375918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464519-type-ii-minocycline-induced-hyperpigmentation-during-long-term-management-of-an-epidermal-growth-factor-receptor-egfr-inhibitor-associated-acneiform-eruption"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.114957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}